|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment显示文摘Hepatocellular carcinoma(HCC)is the fifth most common cause of cancer in the world.According to Barcelona Clinic Liver Cancer modified criteria,patients with early stage disease are candidate to radiofrequency ablation(RFA),while patients with intermediate stage HCC are usually treated by transarterial chemoembolization(TACE).TACE and RFA induce a transient devascularisation effect followed by strong neoangiogenic stimulus.In fact,after these procedures,it has been demonstrated an up-regulation of pro-angiogenic and growth factors such as vascular endothelial growth factor-A,which might contribute to accelerated progression in patients with incomplete response.Several studies have demonstrated that MAP-kinase and AKT pathways,in addition to neo-angiogenesis,have an important role in the development of HCC.In advanced HCC,anti-angiogenic therapy and tyrosine kinases inhibitors showed potential clinical benefit.Actually,a number of clinical studies are ongoing testing these agents in combination with TACE or RFA.In this paper,we have reviewed the most recent preclinical and clinical results of such trials. | Girolamo Ranieri Ilaria Marech Vito Lorusso Veronica Goffredo Angelo Paradiso Domenico Ribatti Cosmo Damiano Gadaleta | 2014 | World Journal of Gastroenterology2014，20，2： | 14 |
| 2 | 胸苷酸合成酶和拓扑异构酶-1及Ki-67对伊立替康联合5-氟脲嘧啶治疗晚期大肠癌的预测价值显示文摘目的探讨胸苷酸合成酶(TS)、拓扑异构酶1(Topo1)和肿瘤增殖指标Ki67对伊立替康(CPT11)联合5氟脲嘧啶(5Fu)治疗晚期大肠癌患者的临床疗效和预后的预测价值。方法采用免疫组化方法检测了CPT11+5Fu一线治疗78例大肠癌患者的TS、Topo1和Ki67的表达,并与化疗疗效和患者的临床预后进行了分析。结果各检测指标的表达水平与临床疗效之间无关,但是临床预后不同。其中,TS低表达患者表现明显长的肿瘤进展时间(TTP,P<0.05)和存活期(OS,P<0.05);Ki67低表达也预示长的OS(P<0.05)。与单个指标相比较,两个指标的联合也不能预测临床疗效,但是对预后的判断作用明显提高。TS低表达、Ki67低表达以及TS和Ki67均低表达患者的中位TTP分别为9,8和17个月(P=0.02);TS低表达、Topo1低表达以及TS和Topo1均低表达患者的中位TTP分别为9,9和13个月(P=0.03);而Topo1低表达、Ki67低表达、Ki67和Topo1均低表达患者的中位TTP分别为8,9和11个月(P=0.05)。其中任何两个指标均低表达肿瘤的TTP和OS均明显长于高表达者(P<0.05)。结论TS、Topo1和Ki67不能预测大肠癌患者CPT11+5Fu的疗效,但对其临床预后有一定的预测作用。其中任何两个指标的联合,比单一指标对患者预后的预测价值明显提高。 | 徐建明 朱步东 Mangia Anita Simone Gianni Montemurro Severino Giuliani Francesco Maiello Evaristo Colucci Giuseppe Paradiso Angelo | 2005 | 中华肿瘤杂志2005，27，5： | 9 |
| 3 | H pylori status and angiogenesis factors in human gastric carcinoma显示文摘AIM: To investigate H pylori expression in gastric cancer patients in relation to primary tumor angiogenic markers, such as microvessel density (MVD), thymidine phospho- rylase (TP), vascular endothelial growth factor receptor-1 (VEGF-R1), p53 and circulating VEGF levels. METHODS: Angiogenic markers were analyzed immu- nohistochemically in 56 primary gastric cancers. H pylori cytotoxin (vacA) and the cytotoxin-associated gene (cagA) amplification were evaluated using PCR assay. Serum H pylori IgG antibodies and serum/plasma circulating VEGF levels were detected in 39 and 38 patients by ELI- SA, respectively. RESULTS: A total of 69% of patients were positive for circulating IgG antibodies against H pylori. cagA-positive H pylori strains were found in 41% of gastric patients. vacA was found in 50% of patients; s1 strains were more highly expressed among vacA-positive patients. The presence of the s1 strain was signifi cantly associ- ated with cagA (P = 0.0001). MVD was signifi cantly cor- related with both tumor VEGF expression (r = 0.361, P = 0.009) and serum VEGF levels (r = -0.347, P = 0.041).Conversely, neither VEGF-R1 expression nor MVD was related to p53 expression. However, H pylori was not related to any angiogenic markers except for the plasma VEGF level (P = 0.026). CONCLUSION: H pylori antigen is related to higher plasma VEGF levels, but not to angiogenic character- istics. It can be hypothesized that the toxic effects of H pylori on angiogenesis occurs in early preclinical dis- ease phase or in long-lasting aggressive infections, but only when high H pylori IgG levels are persistent. | Anita Mangia Annalisa Chiriatti Girolamo Ranieri Ines Abbate Maria Coviello Giovanni Simone Francesco Alfredo Zito Severino Montemurro Antonello Rucci Alfredo Di Leo Stefania Tommasi Pasquale Berloco Jian Ming Xu Angelo Paradiso | 2006 | World Journal of Gastroenterology2006，12，34： | 5 |
| 4 | Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity显示文摘 | Letizia Porcelli Anna E. Quatrale Paola Mantuano Maria G. Leo Nicola Silvestris Jean F. Rolland Enza Carioggia Marco Lioce Angelo Paradiso Amalia Azzariti | 2013 | Molecular Oncology2013，，3： | 2 |
| 5 | Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity显示文摘 | Letizia Porcelli Anna E. Quatrale Paola Mantuano Maria G. Leo Nicola Silvestris Jean F. Rolland Enza Carioggia Marco Lioce Angelo Paradiso Amalia Azzariti | 2012 | Molecular Oncology2012，，： | 1 |
| 6 | EGFR and VEGFR as potential target for biological therapies in HCC cells显示文摘 | Gianluigi Giannelli Concetta Sgarra Letizia Porcelli Amalia Azzariti Salvatore Antonaci Angelo Paradiso | 2007 | Cancer Letters2007，，2： | 1 |
| 7 | Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib(Iressa^(TM))and to the antiangiogenic agent ZD6474:Cytotoxic and biomolecular effects显示文摘瞄准:为了分析 HT-29 和 LoVo 结肠癌房间的延长在试管内暴露的生物效果,排队到 gefitinib (Iressa ) ,表皮的生长的一个禁止者因素受体(EGFR ) 活动,和 ZD6474, KDR 和 EGFR 活动的一个禁止者。方法:房间用也为多达 2 wk 与每药被对待一连续或一断断续续(药暴露的 4 d 每个星期由冲刷的 3 d 列在后面) 时间表。结果:在两种细胞类型,延长了暴露(多达 14 d ) 到 gefitinib 或 ZD6474 生产了治疗时间表坚持、独立的细胞生长的类似的抑制。房间生长上的效果与 p-EGFR 或 p-KDR 表示的显著抑制被联系。有 gefitinib 或 ZD6474 的治疗也禁止了 EGFR 下游的信号分子, p-Erk1/2 和 p-Akt 的表达式,尽管这些效果的大小在治疗和房间线之间变化了。而且,抵抗相关的蛋白质 ABCG2 被显示出显著地在连续暴露的 14 d 以后增加到二药的药的表示。结论:我们断定到 gefitinib 和 ZD6474 的结肠癌房间的长期的暴露不修改他们的细胞毒素的效果,但是它可能在敏感上有效果到古典细胞毒素的药。 | Amalia Azzariti Letizia Porcelli Jian-Ming Xu Grazia Maria Simone Angelo Paradiso | 2006 | World Journal of Gastroenterology2006，12，32： | 1 |
| 8 | Clinical relevance of contrast-enhanced ultrasound in monitoring anti-angiogenic therapy of cancer: Current status and perspectives显示文摘 | Michele Lamuraglia S. Lori Bridal Mathieu Santin Gianni Izzi Olivier Rixe Angelo Paradiso Olivier Lucidarme | 2009 | Critical Reviews in Oncology and Hematology2009，，3： | 1 |
| 9 | The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines显示文摘 | Jian-Ming Xu Amalia Azzariti Giuseppe Colucci Angelo Paradiso | 2003 | Cancer Chemotherapy and Pharmacology2003，，6： | 1 |
| 10 | Microvessel density, mast cell density and thymidine phosphorylase expressionin oral squamous carcinoma显示文摘 | Girolamo Ranieri Angela Labriola Gaetano Achille Gerolmina Florio Alfredo Zito Luciano Grammatica Angelo Paradiso | 2002 | International Journal of Oncology2002，，6： | 1 |
| 11 | The value of new high-throughput technologies for diagnosis andprognosis in solid tumors显示文摘 | Ioana Berindan Neagoe Angelo Paradiso Rosamaria Pinto Simona De Summa Daniela Petriella Oana Tudoran Katia Danza Stefania Tommasi | | Cancer Biomarkers . 2014 (2,3)0，，： | 1 |
| 12 | HER1、HER2和HER3表达水平与IRESSA治疗晚期NSCLC疗效和预后的关系(英文)显示文摘Objective: Biological markers performable in routine practice and able to predict the clinical outcome of advanced non-small cell lung cancer (NSCLC) treated with gefitinib are urgently needed. Methods: We analyzed EGFR / HER2 / HER3 primary tumour immunohistochemical expression in a prospective and consecutive series of 90 Chinese patients. Platinum- pretreated patients received a 250 mg oral dose of gefitinib once daily until disease progression; EGFR / HER2 / HER3 tumour status was related with the clinical outcome in terms of response rate (RR), time to disease progression (TTP), and overall survival (OS). Results: A high expression (scores 2-3) of EGFR, HER2 and HER3 was verified in 16.7%, 43.3% and 21.1% of tumors, respectively. EGFR and HER3 status were not significantly related with response, while the HER2 overexpression result was significantly associated with a higher RR (35.9% vs. 15.7%, P = 0.027). The RR in the 13 patients with both HER2 and HER3 expression was also significantly higher than in the other 77 patients (53.8% vs. 22.1%, P = 0.036). EGFR / HER2 / HER3 status was not significantly correlated with TTP or OS. Conclusion: The HER2 immunohistochemical expression can play a role in the clinical management of Chinese patients with advanced NSCLC who are candidates for gefitinib therapy. | Jianming Xu Emei Gao Yu Han Yang Zhang Suxia Li Xiaoqing Liu Zhiqiang Li Angelo Paradiso | 2008 | The Chinese-German Journal of Clinical Oncology2008，7，8： | 0 |
| 13 | Identification of Tumor Evolution Patterns by Means of Inductive Logic Programming显示文摘In considering key events of genomic disorders in the development and progression of cancer, the correlation between genomic instability and carcinogenesis is cur-rently under investigation. In this work, we propose an inductive logic program-ming approach to the problem of modeling evolution patterns for breast cancer. Using this approach, it is possible to extract fingerprints of stages of the disease that can be used in order to develop and deliver the most adequate therapies to patients. Furthermore, such a model can help physicians and biologists in the elu-cidation of molecular dynamics underlying the aberrations-waterfall model behind carcinogenesis. By showing results obtained on a real-world dataset, we try to give some hints about further approach to the knowledge-driven validations of such hypotheses. | Vitoantonio Bevilacqua Patrizia Chiarappa Giuseppe Mastronardi Filippo Menolascina Angelo Paradiso Stefania Tommasi | 2008 | Genomics, Proteomics & Bioinformatics2008，6，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员